5月5日のプレスリリース
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues.Novartis<概要>Phase III data show patients on pasireotide LAR achieved greater biochemical control, as measured by both GH and IGF-1 levels, versus control group.These data, supported by a previously published Phase III study, are the basis for worldwide regulatory filings for pasireotide LAR in the treatment of acromegaly.<感想>末端肥大症に新薬登場です。クッシング症候群ですでの効能を有しているSigniforが待った肥大症で良好な試験結果を得ました。リンク先:http://www.novartis.com/newsroom/Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotic.Johnson & Johnson<概要>the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many “real world” issues in the treatment of schizophrenia, including some of the most challenging circumstances – recent incarceration and substance abuse.INVEGA® SUSTENNA® showed statistical superiority against the primary endpoint, delaying relapse in patients with schizophrenia, as well as in reducing overall relapse, compared to the most commonly used treatments, daily oral antipsychotics (median 416 days vs. median 226 days; P = 0.011). The risk of relapse was 1.4 times higher (95% CI: 1.09, 1.88, P=0.011) in the oral group versus the INVEGA® SUSTENNA® group<感想>ヤンセンの月1注射のゼプリオンにブルーレターが出たところです。(頻度は臨床試験を上回るものではなかったと思います。)この手の薬は重大な副作用が出たときにどうやって中和するのでしょうか?リンク先:http://www.jnj.com/news/all/GREER® Laboratories, Inc. Launches ORALAIR®, the First and Only Sublingual Allergy Immunotherapy Tablet with a Mix of Five Grass Allergens for the Treatment of Grass Pollen Allergy<概要>Grass allergies are the most common seasonal allergy in the United States1,2 and most people are allergic to more than one type of grass.3 ORALAIR is the first and only FDA approved oral allergy immunotherapy tablet that includes a five grass, mixed pollens allergen extract. These grasses are widely distributed throughout the U.S.<感想>花粉症の舌下減感作療法。アメリカ向けなので、抗原が日本向けではありません。リンク先:http://www.greerlabs.com/files/ORALAIR-Launch-Day-4-30-14.pdf Kinex Receives US FDA Allowance for Oratecan, an Oral Form of Irinotecan with Enhanced Gastrointestinal Absorption, the Second U.S. IND Based on the Orascovery Technology Platform<概要>Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.<感想>イリノテカンの経口剤の第1相試験が開始。Kinexは色々な制がん剤の経口化を研究している会社。FDA INDはパクリタキセルの経口化に続いて2剤目。昔制がん剤の開発をしているときに前期第2相試験が終わったときに世話人の先生からこの制がん剤は切れすぎる、経口剤としては危険が伴うので注意を伴う。ということをいわれたことを思い出しました。注射は医者の監視下で投与されますが、経口は医師の管理外で投与されることに警笛を鳴らしてもらったのだと思います。リンク先:http://www.kinexpharma.com/kinex-receives-us-fda-allowance-for-oratecan-an-oral-form-of-irinotecan-with-enhanced-gastrointestinal-absorption-the-second-u-s-ind-based-on-the-orascovery-technology-platform/今日はここまで。